Navigation Links
Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
Date:3/18/2009

Company estimates sales of pixantrone, if approved, could potentially reach $1 billion by 2014

SEATTLE, March 19 /PRNewswire-FirstCall/ -- Craig Philips, President of Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) reviewed CTI's programs in a presentation at the 8th Annual WBBA Invest Northwest Conference on Wednesday, March 18th . Mr. Philips' highlights focused on CTI's pixantrone program for treatment of aggressive relapsed non-Hodgkin's lymphoma (NHL) and OPAXIO for treatment of non-small cell lung cancer, including:

  • Shared market forecast estimates conducted by CTI based on third-party market research that, if pixantrone were approved in late 2009 by the FDA in the US, and subsequently approved in Europe, the potential combined market could approach $1 billion in sales by 2014 subject to certain market penetration, competitive landscape and pricing assumptions.

  • Summarized positive results from the phase III EXTEND trial of pixantrone in aggressive relapsed NHL for which it met the trial's primary endpoint, with patients treated with pixantrone achieving a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). CTI expects to complete a New Drug Application filing for pixantrone in the second quarter of 2009.

  • Reviewed OPAXIO data in small cell lung cancer and the status of the ongoing phase III study in ovarian cancer. CTI expects to receive an opinion on the Marketing Authorization Application in Europe that is currently under review by the European Medicines Agency in the second half of 2009.

  • Reviewed recent initiatives taken by CTI to reduce expenses incl
    '/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... SAN DIEGO , May 16, 2013  The ... the Association of Bioscience Financial Officers (ABFO) 2013 National Conference, ... will be held May 28-31 at the Hilton San ... finishing touches on this year,s conference and want to ... opportunity to attend," said Brandi Roberts ...
(Date:5/16/2013)... Toronto, Canada (PRWEB) May 16, 2013 ... years and costs over one billion dollars. Despite this ... market. With stakes this high, is your clinical trial ... and deliver the best outcomes? , Dr. Frederic Sax, ... Quintiles, will discuss the use of data, information and ...
(Date:5/16/2013)... May 16, 2013 BioInformatics LLC New ... & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) ... of suppliers in the primary cells market continues to ... types are used most often, how satisfied scientists are ... size and anticipated growth rate. ,  , Additionally, ...
(Date:5/16/2013)... A number of residents in an apartment complex in ... abcactionnews.com, it was no thanks to the infestation of ... to the management and everyone else suffering from the pests ... public to try samples of it to prove it themselves ... 2013 determined that the complex invaded by bed ...
Breaking Biology Technology:Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3Bed Bugs Plague Tarpon Springs Apartment Complex, Non-Pesticide Bed Bug Spray Recommended to Management by My Cleaning Products to Help 2Bed Bugs Plague Tarpon Springs Apartment Complex, Non-Pesticide Bed Bug Spray Recommended to Management by My Cleaning Products to Help 3
... for Pharmaceutical ... ... Codexis, Inc., a private,biotechnology company and leading developer of clean ... California Institute of Technology for preparing and identifying,drug metabolites (substances ...
... Colo., Aug. 29 AspenBio Pharma,Inc. (Nasdaq: APPY ... novel drugs and diagnostics for animals and humans,reported today ... annual Roth,Capital Partners New York Investor Conference to be ... investors are expected to attend the,conference, which will be ...
... of cardiovascular genetics ... ... GeneNews Limited (TSX: GEN),a company focused on developing patient-friendly blood-based ... or medical,condition, today announced that its co-founder and Chief Scientist ...
Cached Biology Technology:Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology 2AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference 2AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference 3GeneNews' Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book 2
(Date:5/17/2013)... AGA Research Foundation announced a new grant that intends ... microbiota, one of today,s most exciting areas of science, ... Research Awards Panel selected Andrew T. Chan, MD, MPH ... Medical School, Boston, as the 2013 AGA-Elsevier Gut Microbiome ... of funding, commencing in July 2013, to test the ...
(Date:5/17/2013)... investigating the interaction of a group of proteins in ... have identified a new target that could increase cell ... University,s School of Biochemistry and published in the ... could eventually lead to new therapies for stroke and ... work by the team which identified a protein, known ...
(Date:5/17/2013)... Societies for Experimental Biology (FASEB) released a new ... trends highlighting the devastating impact of sequestration on the ... follows a May 15th Senate Appropriations Committee hearing featuring ... the $1.6 billion cut the agency sustained in FY ... on the scientific community." , According to data ...
Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2SUMO wrestling cells reveal new protective mechanism target for stroke 2
... - Wheat plants found to be resistant to Hessian ... up rigid defenses. Christie Williams, a research scientist ... and a Purdue University associate professor of entomology, found ... increased production of surface waxes and cutin, a molecule ...
... GALVESTON, Texas Why do people become physically weaker ... stop, or even reverse this process, breaking the link between ... online this Wednesday in the Journal of Clinical Endocrinology ... researchers present evidence that answers to both those questions can ...
... MN Bringing the power of synchrotron light to ... aim of a Memorandum of Agreement (MOA) signed today ... national synchrotron facility, the Canadian Light Source (CLS). ... scientific and product outcomes while improving operating efficiency for ...
Cached Biology News:Resistant wheat rebuilds cell walls when attacked by Hessian flies 2Muscle loss in elderly linked to blood vessels' failure to dilate 2BioBusiness Alliance, Canadian Light Source Synchrotron sign agreement 2
WNV Core Antibody...
Rad51, N-terminal...
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
Goat polyclonal to T7 tag (Agarose) Immunogen: Goats were immunized with MASMTGGQQMG (T7) conjugated to KLH.After multiple immunizations in Freund's adjuvant, serum was collected....
Biology Products: